ALPA
Alpa Laboratories Limited (ALPA) Stock Analysis
Alpa Laboratories Limited is an Indian pharmaceutical company manufacturing formulations and APIs. It supplies generic medicines to domestic and export markets across therapeutic segments. The company operates manufacturing facilities in India. It is a listed small-cap pharma stock.
Healthcare › Drug Manufacturers - Specialty & Generic
₹57.00
-3.83% 1W | -35.30% 52W
Market Cap
120 CR
P/E Ratio
33.9
52W High
₹93.8
52W Low
₹46.1
Div. Yield
0%
Beta
0.9
50 DMA
₹62.9
200 DMA
₹66.5
Profit Margin
3.8%
Inst. Own.
0%
⚡ APPROACHING SUPPORT
⚡ APPROACHING SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25.43 | 32.39 | 27.31 | 23.61 | 21.44 | 24.94 | 26.15 | 39.92 | 19.11 | 26.26 | 29.05 | 31.40 | 23.93 |
| Expenses | 26.57 | 29.04 | 24.88 | 20.10 | 20.91 | 21.62 | 25.41 | 39.72 | 18.68 | 28.51 | 27.54 | 27.80 | 27.89 |
| Operating Profit | -1.14 | 3.35 | 2.43 | 3.51 | 0.53 | 3.32 | 0.74 | 0.20 | 0.43 | -2.25 | 1.51 | 3.60 | -3.96 |
| OPM % | -4.48% | 10.34% | 8.90% | 14.87% | 2.47% | 13.31% | 2.83% | 0.50% | 2.25% | -8.57% | 5.20% | 11.46% | -16.55% |
| Other Income | 4.47 | 2.95 | 3.55 | 3.98 | 5.16 | 6.91 | 8.80 | 2.48 | 11.94 | 3.06 | 0.91 | -0.16 | 5.77 |
| Interest | 0.02 | 0.02 | 0.02 | 0.29 | 0.05 | 0.05 | 0.09 | 0.02 | 0.05 | 0.03 | 0.03 | 0.15 | 0.11 |
| Depreciation | 0.28 | 0.49 | 0.66 | 0.52 | 0.54 | 0.53 | 0.55 | 0.58 | 0.55 | 0.67 | 0.65 | 0.22 | 0.72 |
| Profit before tax | 3.03 | 5.79 | 5.30 | 6.68 | 5.10 | 9.65 | 8.90 | 2.08 | 11.77 | 0.11 | 1.74 | 3.07 | 0.98 |
| Tax % | 0.00% | 0.00% | 14.91% | 46.71% | 0.00% | 20.31% | 0.00% | 201.92% | 0.00% | 0.00% | 9.20% | 55.05% | 0.00% |
| Net Profit | 3.03 | 5.79 | 4.51 | 3.55 | 5.10 | 7.69 | 8.90 | -2.12 | 11.77 | 0.11 | 1.59 | 1.38 | 0.98 |
| EPS in Rs | 1.44 | 2.75 | 2.14 | 1.69 | 2.42 | 3.65 | 4.23 | -1.01 | 5.59 | 0.05 | 0.76 | 0.66 | 0.47 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 57 | 53 | 63 | 62 | 77 | 85 | 97 | 112 | 93 | 109 | 110 | 106 | 111 |
| Expenses | 54 | 47 | 56 | 58 | 76 | 80 | 90 | 101 | 85 | 100 | 105 | 103 | 112 |
| Operating Profit | 3 | 7 | 7 | 4 | 1 | 6 | 8 | 11 | 8 | 9 | 5 | 3 | -1 |
| OPM % | 6% | 13% | 11% | 7% | 1.5% | 7% | 8% | 10% | 9% | 8% | 4.4% | 3.1% | -1.0% |
| Other Income | 2 | 5 | 3 | 5 | 5 | 0 | 4 | 11 | 9 | 14 | 23 | 16 | 10 |
| Interest | 2 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 6 | 1 | 3 | 3 | 3 | 3 | 1 | 2 | 1 | 2 | 2 | 2 | 2 |
| Profit before tax | -3 | 10 | 6 | 5 | 3 | 3 | 11 | 20 | 16 | 21 | 26 | 17 | 6 |
| Tax % | -48% | 30% | 55% | 39% | 63% | 36% | 33% | 28% | 21% | 19% | 24% | 10% | |
| Net Profit | -1 | 7 | 3 | 3 | 1 | 2 | 7 | 14 | 13 | 17 | 20 | 15 | 4 |
| EPS in Rs | -0.67 | 3.26 | 1.20 | 1.34 | 0.48 | 0.88 | 3.45 | 6.70 | 5.98 | 7.98 | 9.27 | 7.13 | 1.94 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 4.0% | 2.0% | 7.0% |
| Profit CAGR | 6.0% | 24.0% | 8.0% |
Shareholding Pattern
Promoters57.29%
FIIs0.36%
Public42.34%
Promoters57.29%
FIIs0.35%
Public42.36%
Promoters57.29%
FIIs0.36%
Public42.35%
Promoters57.19%
FIIs0.38%
Public42.43%
Promoters57.19%
FIIs0.35%
DIIs0.07%
Public42.38%
Promoters57.29%
DIIs0.01%
Public42.70%
Promoters57.29%
FIIs0.50%
Public42.21%
Promoters57.29%
FIIs0.40%
Public42.30%
Promoters57.19%
FIIs0.38%
Public42.43%
Promoters57.19%
FIIs0.35%
DIIs0.07%
Public42.38%
ALPA
Holdings Analysis
Key strengths & risk signals
47
Overall
41
Fundamental
53
Technical
Risks (4)
OVERVALUED! PEG of 5.56 means expensive relative to growth rate.
POOR YEAR! Stock declined 35.3% in the last year.
WEAK POSITION! Current price (57.0) is below both moving averages.
NEGATIVE MOMENTUM! Price declined across timeframes - down 3.8% (1 week), 9.9% (1 month), 16.5% (3 months).
Strengths (4)
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
BULLISH SENTIMENT! In last 30 days: 12 up days, 18 down days. Avg volume on up days: 23,760 vs down days: 17,505. Ratio: 1.36x
APPROACHING OVERSOLD! RSI at 32.3 - watch for reversal.
BELOW MARKET! Beta of 0.90 - slightly less volatile than market.
Fundamental & Technical Analysis
47Overall
41Fundamental
53Technical
Fundamental Breakdown
Growth Quality
13/30
Revenue CAGR: 4.3% (SLOW, 5/15). Profit CAGR: 6.1% (MODERATE, 8/15).
Profit Margin
2/10
LOW MARGIN! 3.8% profit margin - thin profits.
PEG Valuation
0/10
OVERVALUED! PEG of 5.56 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 42.7% public ownership - higher volatility risk.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
5/10
BEARISH TREND! 50-day average (62.9) is below 200-day average (66.5) - negative signal.
Price Position
2/10
WEAK POSITION! Current price (57.0) is below both moving averages.
Trend Pattern
10/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
0/10
POOR YEAR! Stock declined 35.3% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 12 up days, 18 down days. Avg volume on up days: 23,760 vs down days: 17,505. Ratio: 1.36x
RSI
4/5
APPROACHING OVERSOLD! RSI at 32.3 - watch for reversal.
52W Range
2/5
LOWER HALF! Trading at 22.9% of 52W range - weakness visible.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 3.8% (1 week), 9.9% (1 month), 16.5% (3 months).
Beta
4/5
BELOW MARKET! Beta of 0.90 - slightly less volatile than market.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALPA | ₹57.00 | 33.9 | 3.8% | 4.3% | 6.1% | -35.3% | 47 | APPROACHING SUPPORT | -91.5% | -28.6% | +25.1% | -23.9% |
| KREBSBIO | ₹56.00 | – | -55.9% | -23.1% | – | -16.8% | 47 | BREAKDOWN | -52.8% | +8.7% | +27.3% | +2.9% |
| BALAXI | ₹22.30 | 49.6 | 0.5% | -7.1% | -68.6% | -48.5% | 51 | APPROACHING SUPPORT | +333.3% | +116.7% | +14.1% | +14.1% |
| VAISHALI | ₹7.90 | – | 4.1% | 18.0% | -15.2% | -26.8% | 52 | BREAKDOWN | – | +278.0% | – | -15.0% |
| PAR | ₹117.10 | 11 | 13.3% | 11.0% | 1.0% | +21.6% | 66 | BREAKDOWN | +42.7% | +423.3% | +20.3% | +59.6% |
| BALPHARMA | ₹93.10 | 20.5 | 2.2% | 0.1% | 34.7% | +18.7% | 66 | CONSOLIDATING UP | +450.0% | -69.4% | +34.4% | +5.4% |
| NATCAPSUQ | ₹160.00 | – | -8.1% | 3.6% | – | -32.4% | 46 | BREAKDOWN | +1.8% | +14.0% | +7.7% | -16.8% |
| VIVIMEDLAB | ₹7.20 | – | -231.3% | -27.9% | – | +33.1% | 50 | CONSOLIDATION | +2,526.8% | +786.1% | -53.1% | -25.0% |
Data from TradeAlone · Updated daily
No news tagged for ALPA yet.
